What the Evidence Says About Cannabis for Inflammatory Bowel Disease
A review found that while the endocannabinoid system plays a key role in IBD pathogenesis and animal models show therapeutic potential, human evidence is limited to symptomatic relief without proven anti-inflammatory effects.
Quick Facts
What This Study Found
This review examined the evidence for cannabis as a treatment for inflammatory bowel disease (IBD), covering endocannabinoid system science, animal models, epidemiological data, and human studies.
Animal research showed that modulating the endocannabinoid system had therapeutic effects in mouse colitis models. Epidemiological data suggested cannabis use is common among IBD patients, with many reporting symptom improvement.
However, human therapy studies had not yet demonstrated objective anti-inflammatory effects. The available evidence suggested cannabis may provide symptomatic relief (pain, appetite, nausea) without addressing the underlying intestinal inflammation. The review called for large, placebo-controlled trials using objective measures like inflammatory markers, biopsies, and endoscopy.
Key Numbers
No specific trial results were presented. The review synthesized findings across preclinical models (showing endocannabinoid system involvement in IBD pathogenesis), surveys (showing high cannabis use among IBD patients), and limited clinical data.
How They Did This
This was a comprehensive review article in a gastroenterology journal, examining preclinical evidence, epidemiological surveys, and the limited clinical trial data on cannabis and IBD. The review also addressed safety considerations and research gaps.
Why This Research Matters
Many IBD patients use cannabis, and some report significant symptom relief. This review clarifies an important distinction: symptomatic improvement does not necessarily mean the underlying disease is being treated. Without evidence of anti-inflammatory effects, cannabis may mask symptoms while inflammation continues.
The Bigger Picture
The gap between patient-reported benefits and objective clinical evidence reflects a broader challenge in cannabis research. IBD patients often turn to cannabis when standard treatments fail, but without rigorous clinical trials, the risk-benefit ratio remains unclear.
What This Study Doesn't Tell Us
The review highlighted the absence of large, double-blind, randomized controlled trials. Existing human data relied on subjective symptom reports rather than objective inflammatory measures. The review could not determine optimal dosing, formulation, or route of administration for potential therapeutic use.
Questions This Raises
- ?Will controlled trials show that cannabis reduces intestinal inflammation, or only symptoms?
- ?What cannabinoid formulations and delivery methods might be most effective for IBD?
Trust & Context
- Key Stat:
- Symptomatic relief observed in patients but objective anti-inflammatory effects not yet demonstrated
- Evidence Grade:
- This is a comprehensive review drawing on preclinical evidence, epidemiological data, and limited human studies. The overall evidence for cannabis in IBD remains preliminary due to a lack of controlled trials.
- Study Age:
- Published in 2016. Several clinical trials on cannabis and IBD have been conducted since, though evidence of anti-inflammatory effects in humans remains limited.
- Original Title:
- Therapeutic Use of Cannabis in Inflammatory Bowel Disease.
- Published In:
- Gastroenterology & hepatology, 12(11), 668-679 (2016)
- Authors:
- Ahmed, Waseem, Katz, Seymour(2)
- Database ID:
- RTHC-01086
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat inflammatory bowel disease?
Current evidence suggests cannabis may relieve IBD symptoms like pain, nausea, and appetite loss, but it has not been shown to reduce the underlying intestinal inflammation. This is an important distinction because untreated inflammation can lead to complications even when symptoms improve.
Is it safe for IBD patients to use cannabis?
The review noted safety concerns including potential drug interactions, cognitive effects, and the risk of masking symptoms while inflammation persists. The authors recommended reserving cannabis for patients with severe IBD refractory to standard treatments.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01086APA
Ahmed, Waseem; Katz, Seymour. (2016). Therapeutic Use of Cannabis in Inflammatory Bowel Disease.. Gastroenterology & hepatology, 12(11), 668-679.
MLA
Ahmed, Waseem, et al. "Therapeutic Use of Cannabis in Inflammatory Bowel Disease.." Gastroenterology & hepatology, 2016.
RethinkTHC
RethinkTHC Research Database. "Therapeutic Use of Cannabis in Inflammatory Bowel Disease." RTHC-01086. Retrieved from https://rethinkthc.com/research/ahmed-2016-therapeutic-use-of-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.